Vor Biopharma
55 hedge funds and large institutions have $481M invested in Vor Biopharma in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
8% more funds holding
Funds holding: 51 → 55 (+4)
0.01% less ownership
Funds ownership: 4.14% → 4.13% (-0.01%)
16% less capital invested
Capital invested by funds: $571M → $481M (-$90M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.8M |
| 2 |
BlackRock
New York
|
+$5.3M |
| 3 |
JP Morgan Chase
New York
|
+$3.23M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.15M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$7.56M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.29M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$4.63M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.53M |
| 5 |
TOCUITCONY
Trustees of Columbia University in the City of New York
New York
|
-$1.37M |
VOR Hedge Fund Activity: Q3 2021 in Review
55 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q3 2021, worth a combined $481M — down 16% from $571M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VOR positions and 4 closed out — a net gain of 5 holders — while 24 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.8M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $7.56M sold.
- 55 institutional investors held Vor Biopharma (VOR) as of Q3 2021, up from 51 in Q2 2021.
- Funds reported $481M of Vor Biopharma stock for Q3 2021, down 16% quarter-over-quarter.
- 9 funds opened new Vor Biopharma positions in Q3 2021 and 4 closed out, a net change of +5 holders.
- The largest Vor Biopharma buyer in Q3 2021 was Vanguard Group, an estimated $6.8M added.
- The largest Vor Biopharma seller in Q3 2021 was Sectoral Asset Management, an estimated $7.56M sold.
Based on aggregated 13F filings for Q3 2021.